Moderna & merck announce 3-year data for mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated sustained improvement in recurrence-free survival & distant metastasis-free survival versus keytruda in patients with high-risk stage iii/iv melanoma following complete resection

At a median planned follow-up of the phase 2b study at 34.9 months, mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to keytruda alone in these patients the 2.5-year recurrence-free survival rate of mrna-4157 (v940) in combination with keytruda was 74.8% as compared to 55.6% for keytruda alone, with the benefit observed across exploratory subgroups the companies have initiated phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a phase 2/3 study for cutaneous squamous cell carcinoma cambridge, ma and rahway, nj / accesswire / june 3, 2024 / moderna, inc. (nasdaq:mrna) and merck (nyse:mrk), known as msd outside of the united states and canada, today announced the first presentation of results from a planned analysis from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv) following complete resection (n=157). with a median follow-up of approximately three years (34.9 months), adjuvant treatment with mrna-4157 (v940) in combination with keytruda continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (rfs), the primary endpoint of the study, reducing the risk of recurrence or death by 49% (hr [95% ci], 0.510 [0.288-0.906]; two-sided nominal p-value 0.019) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking